RT Journal Article
SR Electronic
T1 Direct oral anticoagulants and venous thromboembolism
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 295
OP 302
DO 10.1183/16000617.0025-2016
VO 25
IS 141
A1 Massimo Franchini
A1 Pier Mannuccio Mannucci
YR 2016
UL http://err.ersjournals.com/content/25/141/295.abstract
AB Venous thromboembolism (VTE), consisting of deep vein thrombosis and pulmonary embolism, is a major clinical concern associated with significant morbidity and mortality. The cornerstone of management of VTE is anticoagulation, and traditional anticoagulants include parenteral heparins and oral vitamin K antagonists. Recently, new oral anticoagulant drugs have been developed and licensed, including direct factor Xa inhibitors (e.g. rivaroxaban, apixaban and edoxaban) and thrombin inhibitors (e.g. dabigatran etexilate). This narrative review focusses on the characteristics of these direct anticoagulants and the main results of published clinical studies on their use in the prevention and treatment of VTE.Direct oral anticoagulants represent an addition for the management of VTE http://ow.ly/4n78VT